72 results
8-K
EX-99.1
COGT
Cogent Biosciences Inc
29 Jul 19
Unum Therapeutics Announces New Appointments to its Board of Directors
7:24am
, a consultancy advising biotech companies on financing, strategy and business development. She brings extensive experience in the pharmaceutical … Strategy and Business Officer at Epizyme, Inc., a late-stage biopharmaceutical company developing novel epigenetic therapies. He has more than 25
8-K
COGT
Cogent Biosciences Inc
22 Feb 21
Departure of Directors or Certain Officers
4:52pm
than 25 years of financial, operations, corporate strategy and compliance expertise in the biotechnology and pharmaceutical industries. He has served … Financial Officer of Synlogic, Inc. where he directed the company’s financial strategy and management as well as facilities and information systems
8-K
EX-99.1
COGT
Cogent Biosciences Inc
9 Aug 22
Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2022 Financial Results
7:15am
of the quarter, and we are confident this will support our go forward strategy into 2025.”
Recent Business Highlights
In June 2022, Cogent reported … events.
In April 2022, the Company presented early data and outlined its strategy to create best-in-class small molecules from the company’s growing
8-K
EX-99.1
COGT
Cogent Biosciences Inc
7 Jan 19
Regulation FD Disclosure
8:02am
tumors High Throughput Screening Novel, multi-stage screening strategy to simulate TME In Vivo Validation Stringent xenograft models to test BOXR … al. Modern Pathology. 2008. Tumor targeting: GPC3 (oncofetal antigen) is well expressed in SqCC tumors “bolt-on” BOXR1030 GPC3 CAR BOXR Strategy
8-K
EX-99.1
u9qr2
3 Jan 19
Unum Therapeutics Announces Transition of Chief Financial Officer
7:23am
8-K
EX-99.1
7vq 6kzeqwow13mf1v
3 Dec 18
Unum Therapeutics Presents Preliminary Results from Ongoing Phase 1 StudyATTCK-17-01 at the 2018 ASH Annual Meeting
7:50am
8-K
EX-99.2
7vo5j12 a1g4h
3 Jan 19
Unum Therapeutics Announces Transition of Chief Financial Officer
7:23am
8-K
EX-99.2
l3jcdy2p3s3a4cds2t7
7 Jan 19
Regulation FD Disclosure
8:02am
8-K
EX-99.1
hbut5
5 Nov 19
Unum Therapeutics Presents Preclinical Data for BOXR1030 at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
2:16pm
8-K
EX-99.2
3m93d30l9uzw9p2 z1t
3 Dec 18
Unum Therapeutics Presents Preliminary Results from Ongoing Phase 1 StudyATTCK-17-01 at the 2018 ASH Annual Meeting
7:50am
8-K
EX-99.1
37rlx56
14 Jun 19
Unum Therapeutics Strengthens and Expands Leadership Team
12:00am
8-K
EX-99.1
grke3nx8iozlhegv5tn7
16 Mar 21
Cogent Biosciences Reports Fourth Quarter 2020
7:15am
8-K
EX-99.1
ba6 a3v4xvi
10 May 22
Cogent Biosciences Reports Recent Business Highlights and First Quarter
7:31am
8-K
EX-99.1
s21t7rt
6 Jul 20
Unum Therapeutics Inc. Announces Acquisition of Kiq LLC
10:31am
8-K
EX-99.1
gybb kqud
9 Nov 20
Cogent Biosciences Reports Third Quarter 2020
7:33am